MedTrace Logo

Effectiveness and Safety of OSTENIL® TENDON in the Treatment of Pain and Restricted Mobility in Tendon Disorders

NCT06681051 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2026-05-19

No results posted yet for this study

Summary

PMCF study to further substantiate the effectiveness and safety of OSTENIL® TENDON in the overall as well as indication-specific treatment of pain and restricted mobility in four different tendon disorders (patella tendon, peroneal tendon, medial epicondylus humeri and iliotibial band) in a real-life clinical setting when used according to the instructions for use.

Conditions

  • Tendinopathy

Interventions

DEVICE

OSTENIL® TENDON

OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.

Sponsors & Collaborators

  • TRB Chemedica AG

    lead INDUSTRY

Principal Investigators

  • Olaf Neubert, Dr. med. · Orthopädie am Kiesteich

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-25
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06681051 on ClinicalTrials.gov